These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36787141)

  • 1. Identification of Bradycardia Following Remdesivir Administration Through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project.
    Devgun JM; Zhang R; Brent J; Wax P; Burkhart K; Meyn A; Campleman S; Abston S; Aldy K;
    JAMA Netw Open; 2023 Feb; 6(2):e2255815. PubMed ID: 36787141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and potential risk factors for remdesivir-associated bradycardia in hospitalized patients with COVID-19: A retrospective cohort study.
    Alsowaida YS; Shehadeh F; Kalligeros M; Mylonakis E
    Front Pharmacol; 2023; 14():1106044. PubMed ID: 36817161
    [No Abstract]   [Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19.
    Ohl ME; Miller DR; Lund BC; Kobayashi T; Richardson Miell K; Beck BF; Alexander B; Crothers K; Vaughan Sarrazin MS
    JAMA Netw Open; 2021 Jul; 4(7):e2114741. PubMed ID: 34264329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
    Orogun L; Chyou TY; Nishtala PS
    Int J Risk Saf Med; 2023; 34(2):87-99. PubMed ID: 37154187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Characteristics and Implications of Bradycardia in COVID-19 Patients Treated with Remdesivir: A Single-Center Retrospective Cohort Study.
    Schreiber A; Bauzon JS; Batra K; Mohammed S; Lee K; Houshmand N; Pham U; Cosme C; Inciong K; Al-Taweel O; Nasser K; Rana J; Sossou C; Go A; Hawwass D; Diep J; Ahsan CH
    Clin Drug Investig; 2022 Sep; 42(9):763-774. PubMed ID: 35978159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precipitating factors of bradycardia after remdesivir administration: ICU admission and cutoff value for declining heart rate.
    Chen YZ; Lin MS; Lin YP; Liu YZ; Yang CJ
    J Microbiol Immunol Infect; 2023 Oct; 56(5):970-976. PubMed ID: 37407291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remdesivir-induced bradycardia in patients hospitalized with SARS-CoV2 infection: a possible vagally-mediated mechanism.
    Filtz A; Carandina A; Fasiello A; Barbetta L; Lombardi R; Cinque F; Rizzi G; Ceriani E; Furlan L; Bellocchi C; Fracanzani AL; Hu C; Cogliati C; Canetta C; Peyvandi F; Montano N; Tobaldini E
    Intern Emerg Med; 2023 Mar; 18(2):359-366. PubMed ID: 36539604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remdesivir treatment and clinical outcome in non-severe hospitalized COVID-19 patients: a propensity score matching multicenter Italian hospital experience.
    Attena E; Caturano A; Annunziata A; Maraolo AE; De Rosa A; Fusco FM; Halasz G; Dall'Ospedale V; Conte M; Parisi V; Galiero R; Sasso FC; Fiorentino G; Russo V
    Eur J Clin Pharmacol; 2023 Jul; 79(7):967-974. PubMed ID: 37212843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data.
    Singh A; Kamath A
    Expert Opin Drug Saf; 2021 Dec; 20(12):1559-1564. PubMed ID: 34328807
    [No Abstract]   [Full Text] [Related]  

  • 11. Transient asymptomatic bradycardia and remdesivir in COVID-19 patients.
    Adamo G; Amata M; Cannizzaro N; Chessari C; Sapienza GM; Capizzi GM; Battaglia S; Benfante A; Scichilone N
    Minerva Med; 2023 Aug; 114(4):463-468. PubMed ID: 35332758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database.
    Jung SY; Kim MS; Li H; Lee KH; Koyanagi A; Solmi M; Kronbichler A; Dragioti E; Tizaoui K; Cargnin S; Terrazzino S; Hong SH; Abou Ghayda R; Kim NK; Chung SK; Jacob L; Salem JE; Yon DK; Lee SW; Kostev K; Kim AY; Jung JW; Choi JY; Shin JS; Park SJ; Choi SW; Ban K; Moon SH; Go YY; Shin JI; Smith L
    Clin Transl Sci; 2022 Feb; 15(2):501-513. PubMed ID: 34719115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Asymptomatic Bradycardia With Incident Cardiovascular Disease and Mortality: The Multi-Ethnic Study of Atherosclerosis (MESA).
    Dharod A; Soliman EZ; Dawood F; Chen H; Shea S; Nazarian S; Bertoni AG;
    JAMA Intern Med; 2016 Feb; 176(2):219-27. PubMed ID: 26785103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Remdesivir Treatment With Mortality Among Hospitalized Adults With COVID-19 in the United States.
    Chokkalingam AP; Hayden J; Goldman JD; Li H; Asubonteng J; Mozaffari E; Bush C; Wang JR; Kong A; Osinusi AO; Gottlieb RL
    JAMA Netw Open; 2022 Dec; 5(12):e2244505. PubMed ID: 36454570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bradycardia and Outcomes in COVID-19 Patients on Remdesivir: A Multicenter Retrospective Study.
    Umeh CA; Maguwudze S; Kaur H; Dimowo O; Naderi N; Safdarpour A; Hussein T; Gupta R
    Cardiol Res; 2023 Jun; 14(3):192-200. PubMed ID: 37304919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remdesivir-induced Bradycardia is not Associated with Worse Outcome in Patients with COVID-19: A Retrospective Analysis.
    Pantazopoulos I; Mavrovounis G; Dimeas G; Zikos N; Pitsikou M; Rousogianni E; Mermiri M; Michou A; Spanos M; Maniotis C; Chalkias A; Laou E; Zakynthinos G; Chatzis D; Gourgoulianis K
    Am J Cardiovasc Drugs; 2022 Nov; 22(6):705-710. PubMed ID: 36002783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Permanent Pacemaker Placement Secondary to Remdesivir Induced Bradycardia: A Case Report.
    Khan S; Mustafa A; Elhosseiny SM; Rizvi T; Lafferty J
    Cureus; 2022 Oct; 14(10):e30923. PubMed ID: 36465748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remdesivir associated sinus bradycardia in patients with COVID-19: A prospective longitudinal study.
    Hajimoradi M; Sharif Kashani B; Dastan F; Aghdasi S; Abedini A; Naghashzadeh F; Mohamadifar A; Keshmiri MS; Noorali S; Lookzadeh S; Alizadeh N; Siri MA; Tavasolpanahi M; Abdolmohammadi Y; Shafaghi M; Rouhani ZS; Shafaghi S
    Front Pharmacol; 2022; 13():1107198. PubMed ID: 36733376
    [No Abstract]   [Full Text] [Related]  

  • 20. Association of Remdesivir use with bradycardia: A systematic review and meta-analysis.
    Ishisaka Y; Aikawa T; Malik A; Kampaktsis PN; Briasoulis A; Kuno T
    J Med Virol; 2023 Aug; 95(8):e29018. PubMed ID: 37539782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.